| Market Cap | 298.30M | P/E | - | EPS this Y | 21.70% | Ern Qtrly Grth | - |
| Income | -88.38M | Forward P/E | -1.66 | EPS next Y | 29.40% | 50D Avg Chg | -19.00% |
| Sales | 13.81M | PEG | -0.03 | EPS past 5Y | - | 200D Avg Chg | -7.00% |
| Dividend | N/A | Price/Book | 1.73 | EPS next 5Y | 21.22% | 52W High Chg | -47.00% |
| Recommedations | 2.70 | Quick Ratio | 3.17 | Shares Outstanding | 96.21M | 52W Low Chg | 37.00% |
| Insider Own | - | ROA | -34.89% | Shares Float | 48.61M | Beta | 0.88 |
| Inst Own | 17.75% | ROE | -72.64% | Shares Shorted/Prior | 298.51K/293.69K | Price | 1.48 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 240,648 | Target Price | 5.33 |
| Oper. Margin | -2,914.90% | Earnings Date | Jul 30 | Volume | 450,974 | Change | -8.07% |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.